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Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed
after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw
in a Chron’s disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it
has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case. On August, 2014, a 63-
year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented
referring pain in the right mandible. Results. This patient presented with nonexposed osteonecrosis of the jaw after placement,
on September, 2010, of four titanium fixtures in the mandible. Conclusions. The authors suggest that the biologic therapy with an
anti-TNF-𝛼 antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.
1. Introduction
Osteonecrosis of the jaw related to Bisphosphonate (BRONJ)
and, recently, Denosumab related osteonecrosis of the jaws
(DRONJ) and other medicaments such as antiangiogenic
agents (MRONJ) has been described [1–3]. Adalimumab
(Humira, Human Monoclonal Antibody in Rheumatoid
Arthritis) is a human monoclonal TNF-𝛼 antibody used to
threat rheumatoid arthritis, juvenile idiopathic arthritis, pso-
riatic arthritis, ankylosing spondylitis, plaque psoriasis, and
Chron’s disease in case of other drugs’ failure. Adalimumab
binds to tumor necrosis factor-alpha (TNF-𝛼). TNF-𝛼 nor-
mally binds to TNF-𝛼 receptors, which leads to the inflamma-
tory response of autoimmune diseases. By binding to TNF-𝛼,
Adalimumab reduces this inflammatory response. Common
side effects include redness, itching, pain, or swelling at the
injection site (it is administered by subcutaneous injection),
and because TNF-𝛼 is part of the immune system that pro-
tects the body from infection, treatment with Adalimumab
may increase the risk of infections such as tuberculosis, while
rarely worsening or initiation of congestive heart failure or
of a multiple sclerosis/neurological disease, a lupus-like
syndrome, a promotion of lymphoma, andpancytopenia have
been reported [4]. Just one case of osteonecrosis of the jaw in a
Crohn’s disease patient following a course of Bisphosphonate
andAdalimumab therapy has been recently described, so that
it has been supposed that this medication could promote
manifestation of osteonecrosis [5]; to the best of our knowl-
edge, we describe the first case of osteonecrosis of the jaws
that could be consequent to the use of Adalimumab to treat
idiopathic arthritis in a woman.
2. Case Report
A 63-year-old female presented to our center on August 2014
referring pain in the right mandible. No history of smoking
or alcohol abuse was referred. Comorbidities include obesity
and idiopathic arthritis treated with medical treatment with
Salazopyrin on 2009 and with Adalimumab (1 injection every
two weeks) from 2010 to 2013: during this period, improve-
ment of symptoms has been referred by the patient. Her
physician also proposed a treatmentwith glucocorticoids, but
she refused because of side effects. She referred 4.7 (caries)
and 4.8 (impacted tooth) extraction on 2008, before starting
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Figure 1: Orthopantomography (OPT) performed on 2009 (a), on May, 2010 (b), on September, 2010 (c), on May, 2011 (d), on August, 2011
(e), and on August, 2014 (f). The last one revealed osteosclerosis, osteolysis, and subperiosteal bone deposition and persistence of extraction
socket.
any treatment for idiopathic arthritis. An orthopantomogra-
phy (OPT) performed on 2009, before starting treatmentwith
Humira, did not show bone alterations (Figure 1(a)). OnMay,
2010, two titanium fixtures were positioned in the maxilla
(1.5 and 2.5) (Figure 1(b)) and, on September-October, 2010,
four titanium fixtures were put in the mandible by her dentist
(3.6, 3.7, 4.6, and 4.7) (Figure 1(c)). On June, 2011, the one
positioned in the region of 4.7 was lost, and it was decided
to reposition it about 1 month later. On May, 2011, the fixture
positioned in the region of 3.6 was lost too (Figure 1(d)), and,
moreover, one month later, after appearance of pain in the
right mandible, the fixture in the region of 4.7 was removed
(Figure 1(e)). A CT scan was performed (Figure 2); because
of difficult healing, patient underwent curettage medications
with local antibiotics (Rifocin) for about 2-3 months. Patient
referred persistence of pain, partially resolved after systemic
antibiotic therapy (amoxicillin + clavulanic acid 1 gr twice
a day) (Figure 1(e)). A static whole body bone scintigraphy
revealed an intensive trace uptake at the right mandible (Fig-
ure 3). Nevertheless, no remission of pain was referred and
patient underwent systemic therapy with paracetamol and
eventually ketorolac in order to control it. Occasionally sys-
temic antibiotic therapy was administered in order to control
swelling of the right mandible, and partial resolution of pain
has been described. On May, 2014, fixture removal (the one
positioned in the site of 4.6) was performed and temporary
remission of pain was referred; on July, 2014, due to the per-
sistence of pain, extraction of 4.5 was performed. Orthopan-
tomography revealed osteosclerosis, osteolysis, and subpe-
riosteal bone deposition and persistence of extraction socket
(Figure 1(f)). Nevertheless, the patient came to our attention
on August 2014 referring recurrence of pain; on the basis
of clinical history (Figure 4) and radiological imaging, such
as CT scan showing sequestrum, diagnosis of MRONJ with
nonexposed necrotic bone was suspected (Figure 5). We con-
sidered the patient to be at Stage 0 (nonexposed bone variant)
because she presented with no clinical evidence of necrotic
bone but presented with nonspecific symptoms and clinical
and radiographic findings [1] (odontalgia not explained by
an odontogenic cause and aching bone pain in the body of
the mandible, loosening of teeth not explained by chronic
periodontal disease, alveolar bone loss or resorption not
attributable to chronic periodontal disease, changes to trabec-
ular pattern dense woven bone, and persistence of unremod-
eled bone in extraction sockets and regions of osteosclerosis
involving the alveolar bone and/or the surrounding basilar
bone) (Figure 6).
The patient reported good pain control using medical
therapy consisting in FANS and antibiotics up toMarch, 2015.
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Figure 2: CT Dentascan scan performed on July, 2011, showing sequestrum.
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Figure 3: Static whole body bone scintigraphy performed on October, 2013, revealed an intensive trace uptake at the right mandible.
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Figure 4: Schematic view of disease progression.
Figure 5: Postoperative control in 2015 showing the healing of the mucosa after extraction of tooth 4.5 and curettage of the bone.
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Figure 6: CT scan performed on April, 2015. (a) Panorex view showing sequestrum, (b) axial view, and (c) 3D reconstruction.
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3. Discussion
Osteonecrosis of the jaw can be usually observed as an
adverse reaction to some medications or to radiotherapy:
histologically, it appears similar to osteomyelitis, and it is not
clear whether infection is the cause or consequence of bone
exposure [6–8]. The term MRONJ has been created in order
to identify “Medication-Related Osteonecrosis of the Jaw,”
observed after the use of antiresorptive (Denosumab) and
antiangiogenic therapies, other than Bisphosphonates [1]. In
particular, in the last 2014 AAOMS Position Paper [1], it has
been assessed that diagnosis of MRONJ can be done if the
following are present:
(i) Current or previous treatment with antiresorptive or
antiangiogenic agents.
(ii) Exposed bone or bone that can be probed through
an intraoral or extraoral fistula(e) in the maxillofacial
region that has persisted for longer than 8 weeks.
(iii) No history of radiation therapy to the jaws or obvious
metastatic disease of the jaws.
Nevertheless, some cases of medication-related ONJ with-
out bone exposure have been described [9]. It is largely
reported that BRONJ is caused by apoptosis of osteoclasts,
disturbance of osteoclast progenitor cell differentiation and
enzyme activity, antineovascularization, and destruction of
bone microstructure caused by bone deposition [9, 10].
DRONJ is related to inhibition of the receptor activator of
nuclear factor kappa-B ligand (RANKL), resulting in osteo-
clast function inhibition. Differently from Bisphosphonate,
the return of bone turnover to normal can be evidenced about
sixmonths after drug injection [2].The use of glucocorticoids
has been demonstrated to lead to osteoblast inhibition and
to bone resorption [11]. Also, antiangiogenic medications,
such as Bevacizumab and Rituximab, have been found to be
implicated in the pathogenesis of ONJ [1, 12, 13].
TNF inhibitors, such as Adalimumab, seem to be able to
arrest systemic bone loss assessed by bone mineral density
and bone turnover markers in rheumatoid arthritis; nev-
ertheless, evidences of the effect of anti-TNF treatment in
preventing fractures are still scarce [14].
It has been described that TNF-𝛼 has an important
effect on systemic bone loss in rheumatoid arthritis, since it
enhances osteoclasts activity, differentiation and activation,
and osteoblasts production and proliferation resulting in an
inhibition on bone turnover markers demonstrated by some
studies [14].
Nevertheless, no cases related to the use of other drugs
have been described, except one in which the use of Adal-
imumab has been hypothesized to improve necrosis caused
by Bisphosphonates. It has been supposed that anti-TNF-𝛼
treatment could cause an inhibition of bone turnover medi-
ated by a reduction of RANKL which could already be shown
in patients with rheumatoid arthritis and anti-TNF-𝛼 therapy
[5]. Another hypothesis is the fact that the induced apoptosis
of activated humanmonocytes can lead to worsening of bone
repair after jaw necrosis. Nevertheless, since one of the side
effects described after Adalimumab treatment are infectious
complications due to immunosuppression, it can be proposed
that osteonecrotic lesions of the jaws can “occur because of
spreading ongoing infections” [5, 15].
Local factors related to ONJ are dentoalveolar surgery,
denture use, and preexisting inflammatory dental disease [1].
In case of nonexposed Bisphosphonate-related osteonecrosis
and asymptomatic patients (no clinical evidence of infection
and radiographic findings can be present), only follow-up
is advocated [10]; in our case, only pain was referred, and
FANS associated with systemic antibiotics were adminis-
tered in order to control it. A chronic infection was also
present, and patient referred multiple local medications to
gain healing after fixture removal. Radiological signs include
osteosclerosis, cortical disruption, osteolysis, subperiosteal
bone deposition, thickening of lamina dura, and widening
of periodontal ligament; in addiction, surface irregularity
and persistent sockets strictly correlate with ONJ [16, 17].
Osteosclerosis is due to mineralization in the absence of
balanced bone resorption, and the persistence of extrac-
tion sockets results from marked inhibition of remodeling
following removal of the tooth [17]. In our case report,
CT scan showed signs of bone sequestrum and analyz-
ing previous OPT signs of osteosclerosis and subperiosteal
bone deposition were present. Delayed healing after fix-
ture removal and persistence of pain, associated with these
radiological findings and bone scintigraphy, showed positive
tracer led us to suspect diagnosis of MRONJ related to
Adalimumab [18]. Nevertheless, further case reports are
required in order to confirm the hypothesis but this clin-
ical case suggests that a dental exam is indicated before
prescription of biological drugs like Adalimumab. In those
patients, periodic dental checkup can be recommended too.
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